Curis, Inc. is a biotechnology company in the US that develops drug candidates to treat human cancers. Their clinical stage drug candidates, including Emavusertib and CI-8993, are in Phase 1/2 trials for treating non-hodgkin lymphomas and acute myeloid leukemia. The company also has collaboration agreements with F. Hoffmann-La Roche Ltd. and Genentech Inc. and Aurigene Discovery Technologies Limited for drug development and commercialization.